News for Takeda Pharmaceutical Company Limited (4502.S)

Incyte (Nasdaq:INCY) today announced that data from numerous programs in its hematology/oncology portfolio will be presented at the 2025 European Hematology As

[url="]Takeda[/url] ([url="]TSE:4502/NYSE:TAK[/url]) today announced that the European Commission (EC) approved ADCETRIS® (brentuximab vedotin) in combination

Takeda ([url="]TSE:4502/NYSE:TAK[/url]) today announced that applications are now open for its Innovators in Science Award. This prestigious global award, orig

Takeda (TAK) opens applications for the 2026 Innovators in Science Award, focusing on gastrointestinal and inflammatory diseases, neuroscience, and oncolog

Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2025, provided an update on progress toward achieving key corporate obj

Takeda Pharmaceutical Company Limited (NYSE:TAK) Q4 2024 Results Conference Call May 8, 2025 6:00 AM ETCompany ParticipantsChristopher O’Reilly - Head,...

\nBioLife Plasma Services, part of Takeda (TSE:4502/NYSE:TAK), today announced that it has begun introducing the new Fresenius Kabi Adaptive Nomogram across its

Takeda Pharmaceutical Company Limited recently awarded $13.8 million to U.S. nonprofits to promote healthy eating and STEM education. The investment und

Incyte (Nasdaq:INCY) today reports 2025 first quarter financial results, and provides a status update on the Company's clinical development portfolio.

Takeda boosts profit margins with AI-driven growth, FY2024 guidance upgrade, share buyback plan & promising drug launches.

Protagonist Therapeutics, Inc. (PTGX) and Takeda Pharmaceutical Company Limited (TAK) Monday announced positive topline results from the Phase 3 VERIFY study of rusfertide in Patients with Polycythemia Vera, a type of blood cancer.

Protagonist Therapeutics, Inc. (”œProtagonist”) ([url="]NASDAQ:PTGX[/url]) and Takeda ([url="]TSE:4502/NYSE:TAK[/url]) today announced positive topline resu

Healthcare, which includes numerous businesses that offer patient care, conduct research and development of novel treatments, and design, produce, and distribute diagnostic tools and tests, takes the ...

We recently compiled a list of the 12 Best Japanese Stocks To Buy in 2025. In this article, we are going to take a look at where Takeda Pharmaceutical Company Limited (NYSE:TAK) stands against the other...

Takeda Pharmaceutical Company Limited (NYSE:TAK) Q3 2025 Results Conference Call January 30, 2025 5:30 AM ETCompany ParticipantsChristopher O’Reilly - Head,...

CEO Christophe Weber to retire from Takeda in June 2026 after 12 years Julie Kim, president of the U.S. Business Unit, named to succeed Weber after multi-year suc…

Revenue Growth of +9.8% at Actual Exchange Rates (AER); +4.5% at Constant Exchange Rate (CER) Driven by Strong Momentum of Growth & Launch Products (+14.6% at CER) …

/PRNewswire-PRWeb/ -- The International Society of Pharmaceutical Engineering (ISPE) has announced the 2025 Facility of the Year submission finalists. Each of...

PR NewswireSAN DIEGO, Jan. 27, 2025 - Neurocrine Obtains Exclusive Worldwide Development and Commercialization Rights Excluding Japan and Converts to